摘要
1966年 db基因发现后,其被确定为在db/db小鼠血液输送过程中产生的过多的饱足因子,但未对此作出回应。db/db小鼠模型被2型糖尿病广泛应用,其在人类疾病中具有表型复制特征并能引发多种并发症包括肥胖,葡萄糖耐量进行性恶化,高血压和高脂血症等。与非糖尿病组相比,db/db小鼠模型组有肝糖原水平持续升高现象,最有可能是由于摄食过多。在透射电子显微镜下,肝糖原通常呈现出一种复合的菜花状形态,大的“α颗粒”(在一定范围的大小)组成较小的“β颗粒”并结合在一起。新研究已探讨了肝糖原分子的大小分布,发现在db/db小鼠模型中,α颗粒比健康小鼠中更易破碎,并能容易地分裂为小的β颗粒。有证据表明,较小的糖原颗粒与糖原磷酸化酶—参与糖原降解的关键酶结合更紧密,并在体外降解更迅速。因此,无法形成稳定的大糖原α颗粒,由此预测将导致葡萄糖的降解更快,受控更少,但其对血糖控制的影响仍有待进一步充分阐明。然而,本文旨在“抢救”更易碎的糖尿病肝糖原以减少2型糖尿病中肝葡萄糖的输出,为其提供一个潜在的治疗靶点。
关键词: Db/db
图形摘要
Current Drug Targets
Title:Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?
Volume: 16 Issue: 10
Author(s): Mitchell A. Sullivan, Brooke E. Harcourt, Ping Xu, Josephine M. Forbes and Robert G. Gilbert
Affiliation:
关键词: Db/db
摘要: After the discovery of the db gene in 1966, it was determined that a blood-borne satiety factor was produced excessively, but was not responded to, in db/db mice. This model for type 2 diabetes is widely used since it phenocopies human disease and its co-morbidities including obesity, progressive deterioration in glucose tolerance, hypertension and hyperlipidaemia. Db/db mice, unlike their non-diabetic controls, have consistently elevated levels of liver glycogen, most likely due to hyperphagia. In transmission electron micrographs, liver glycogen usually shows a composite cauliflower-like morphology of large “α particles” (with a wide range of sizes) made up of smaller “β particles” bound together. New studies have explored the size distribution of liver glycogen molecules and found that α particles in db/db mice are more chemically fragile than those in healthy mice, and can readily break apart to smaller β particles. There is evidence that smaller glycogen particles have a higher association with glycogen phosphorylase, a key enzyme involved in glycogen degradation, as well as being degraded more rapidly in vitro; therefore the inability to form stable large glycogen α particles is predicted to result in a faster, less controlled degradation into glucose. The implications of this for glycaemic control remain to be fully elucidated. However, “rescuing” the more fragile diabetic glycogen to decrease hepatic glucose output in type 2 diabetes, may provide a potential therapeutic target which is the subject of this review.
Export Options
About this article
Cite this article as:
Mitchell A. Sullivan, Brooke E. Harcourt, Ping Xu, Josephine M. Forbes and Robert G. Gilbert , Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?, Current Drug Targets 2015; 16 (10) . https://dx.doi.org/10.2174/1389450116666150727123115
DOI https://dx.doi.org/10.2174/1389450116666150727123115 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Role of Statins in Re-Endothelialization
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Current Respiratory Medicine Reviews Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Preeclampsia – Aetiopathogenesis and Clinical Management
Current Pharmaceutical Biotechnology The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Neonatal Environment and Neuroendocrine Programming of the Peripheral Respiratory Control System
Current Pediatric Reviews Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Evidence of 2 Populations of Mephedrone Abusers by Hair Testing. Application to 4 Forensic Expertises
Current Neuropharmacology Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation
Current Drug Targets Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis
CNS & Neurological Disorders - Drug Targets subject Index To Volume 3
Current Drug Metabolism Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Current Pharmacogenomics and Personalized Medicine Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry